^
Association details:
Evidence:
Evidence Level:
Resistant: B - Late Trials
Title:

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Published date:
12/09/2021
Excerpt:
HLA-A*03 was associated with shorter progression-free survival in patients receiving ICI in the JAVELIN Renal 101 randomised clinical trial for renal cell carcinoma (avelumab plus axitinib; HR 1·59 per HLA-A*03 allele, 1·16–2·16; p=0·0036), but not in those receiving control (sunitinib) therapy....HLA-A*03 is a predictive biomarker of poor response to ICI.
DOI:
https://doi.org/10.1016/S1470-2045(21)00582-9